Two Phase 3 trials led by Northwestern University show that the experimental weekly weight-loss drug retatrutide substantially reduces knee pain in obese patients with knee osteoarthritis. The trials included more than 1,000 participants, and those receiving the highest dose lost an average of about 25% of their body weight. When the results of the two trials were combined, approximately two-thirds of participants receiving the medication experienced at least a 50% reduction in knee pain, compared with 38% in the placebo group. Participants also showed decreases in blood pressure, blood lipids and markers of systemic inflammation. The results were published on Nov. 8 in the New England Journal of Medicine. The Trials TRIUMPH-4 and TRIUMPH-1-OA focused on pain and weight changes, respectively. The study assessed pain using the WOMAC Pain index and had participants record their symptoms daily through a mobile app.

Source:ScienceDaily · Read Original